Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
July 30, 2019
Assignees:
Institut National de la Sante et de la Recherche Medicale, OSE Immunotherapeutics
Inventors:
Caroline Mary, Nicolas Poirier, Bernard Vanhove
Abstract: The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab? antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.
Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
Type:
Application
Filed:
January 26, 2017
Publication date:
June 15, 2017
Applicants:
OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Bernard Vanhove, Caroline Mary, Flora Coulon
Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Type:
Application
Filed:
December 21, 2016
Publication date:
April 27, 2017
Applicants:
OSE Immunotherapeutics, Institut National de la Sante et de la Recherche M edicale (INSERM)
Inventors:
Caroline Mary, Nicolas Poirier, Bernard Vanhove
Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
Type:
Grant
Filed:
January 13, 2010
Date of Patent:
March 7, 2017
Assignees:
OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Bernard Vanhove, Caroline Mary, Flora Coulon
Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Type:
Grant
Filed:
July 8, 2014
Date of Patent:
February 7, 2017
Assignees:
OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Caroline Mary, Nicolas Poirier, Bernard Vanhove
Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
Type:
Grant
Filed:
October 4, 2012
Date of Patent:
September 20, 2016
Assignees:
OSE IMMUNOTHERAPEUTICS, INSTITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE
Inventors:
Sophie Brouard, Le Hoa Mai, Caroline Mary, Nicolas Poirier, Jean-Paul Soulillou, Bernard Vanhove